Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 36Terminated 10Active not recruiting 7Recruiting 5Unknown 3Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Renal Insufficiency 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 284Drug Therapy 244apatinib 242Bevacizumab 230camrelizumab 214Etoposide 200Irinotecan 177Doxorubicin 175Leucovorin 162Dexamethasone 160sintilimab 142pembrolizumab 140anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Interventional × Diphenhydramine × Clear all
NCT04308837 2023-11-14

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Icahn School of Medicine at Mount Sinai

Phase 2 Unknown
29 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT00324467 2021-07-22

LYTPET

British Columbia Cancer Agency

Phase 2 Unknown
150 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡